Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected billions of individuals and is the cause of the current global coronavirus disease 2019 (COVID-19) pandemic. We previously developed an mRNA vaccine (LVRNA009) based on the S protein of the Wuhan-Hu-1 strain; the phases I...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianglong, Liu, Qi, Liu, Jun, Fang, Zihui, Luo, Liping, Li, Shuang, Lei, Yixin, Li, Zhi, Jin, Jing, Xie, Ronglin, Peng, Yucai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693459/
https://www.ncbi.nlm.nih.gov/pubmed/36366316
http://dx.doi.org/10.3390/vaccines10111807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693459/
https://www.ncbi.nlm.nih.gov/pubmed/36366316
http://dx.doi.org/10.3390/vaccines10111807

Ejemplares similares